Table 1.
Patient baseline characteristics
| Characteristics | Phase 1b (n = 15), n (%) | Phase 2 (n = 113), n (%) |
|---|---|---|
| Age, years | ||
| Median | 54 | 54 |
| Range | 24–69 | 20–70 |
| > 60 | 4 (26.7) | 33 (29.2) |
| Male | 9 (60.0) | 72 (63.7) |
| Ann Arbor staging | ||
| Stage I | 0 (0) | 5 (4.4) |
| Stage II | 1 (6.7) | 19 (16.8) |
| Stage III | 4 (26.7) | 32 (28.3) |
| Stage IV | 10 (66.7) | 57 (50.4) |
| B symptoms | 10 (66.7) | 66 (58.4) |
| IPI | ||
| 0–1 | 0 (0) | 34 (30.1) |
| 2 | 6 (40.0) | 33 (29.2) |
| 3 | 4 (26.7) | 24 (21.2) |
| 4–5 | 5 (33.3) | 22 (19.5) |
| Pathology subtypes | ||
| AITL | 9 (60.0) | 41 (36.3) |
| PTCL-NOS | 1 (7.0) | 48 (42.5) |
| ALCL, ALK- | 4 (26.0) | 17 (15.0) |
| EATL | 1 (7.0) | 7 (6.2) |
AITL, angioimmunoblastic T cell lymphoma; PTCL-NOS, peripheral T cell lymphoma-not otherwise specified; ALCL, anaplastic large cell lymphoma; EATL, enteropathy-associated T-cell lymphoma; IPI, international prognostic index.